Techniques for Downstream process for Biologic Drugs and Vaccines


Book Description

Techniques for Downstream process for Biologic Drugs and Vaccines provides comprehensive technologies involved in processing postharvest broth to separate the target biological therapeutic products of extracellular or intercellular aspects in nature - to its highest purification form, and to thus make it acceptable to end users. The technologies involved in the post-harvesting of fermented broth are explained in this comprehensive resource in a simplified manner with different case studies to help non-engineering students and scientists easily capture the basic principle of biomass processing technologies and their applications in new projects related to the development and manufacturing of therapeutic bio-products. As conceptual development of biotechnology has taken new shape and style with the integration of medical sciences, physical science, and engineering, and has thus begun the need for the development of microbial or cell line process technology and application for large-scale isolation and purification of metabolites or vaccines through the fermentation process, this book covers the most important aspects. - Provides insights into the conceptual strategic drive for manufacturing innovative biologically derived therapeutic compounds for commercial purposes - Focuses on how to execute biopharmaceutical portfolio trends to bring sustainable manufacturing process as per guidelines of international regulatory acts - Highlights emerging trends in medical sciences on tissue engineering, regenerative medicine, personalized medicines, and various innovative techniques on immunotherapy to fight against life-threatening diseases




Continuous Manufacturing for the Modernization of Pharmaceutical Production


Book Description

On July 30-31, 2018, the National Academies of Sciences, Engineering, and Medicine held a workshop titled Continuous Manufacturing for the Modernization of Pharmaceutical Production. This workshop discussed the business and regulatory concerns associated with adopting continuous manufacturing techniques to produce biologics such as enzymes, monoclonal antibodies, and vaccines. The participants also discussed specific challenges for integration across the manufacturing system, including upstream and downstream processes, analytical techniques, and drug product development. The workshop addressed these challenges broadly across the biologics domain but focused particularly on drug categories of greatest FDA and industrial interest such as monoclonal antibodies and vaccines. This publication summarizes the presentations and discussions from the workshop.




The Anthrax Vaccine


Book Description

The vaccine used to protect humans against the anthrax disease, called Anthrax Vaccine Adsorbed (AVA), was licensed in 1970. It was initially used to protect people who might be exposed to anthrax where they worked, such as veterinarians and textile plant workers who process animal hair. When the U. S. military began to administer the vaccine, then extended a plan for the mandatory vaccination of all U. S. service members, some raised concerns about the safety and efficacy of AVA and the manufacture of the vaccine. In response to these and other concerns, Congress directed the Department of Defense to support an independent examination of AVA. The Anthrax Vaccine: Is It Safe? Does It Work? reports the study's conclusion that the vaccine is acceptably safe and effective in protecting humans against anthrax. The book also includes a description of advances needed in main areas: improving the way the vaccine is now used, expanding surveillance efforts to detect side effects from its use, and developing a better vaccine.




Biochemical Engineering and Biotechnology


Book Description

Biochemical Engineering and Biotechnology, 2nd Edition, outlines the principles of biochemical processes and explains their use in the manufacturing of every day products. The author uses a diirect approach that should be very useful for students in following the concepts and practical applications. This book is unique in having many solved problems, case studies, examples and demonstrations of detailed experiments, with simple design equations and required calculations. - Covers major concepts of biochemical engineering and biotechnology, including applications in bioprocesses, fermentation technologies, enzymatic processes, and membrane separations, amongst others - Accessible to chemical engineering students who need to both learn, and apply, biological knowledge in engineering principals - Includes solved problems, examples, and demonstrations of detailed experiments with simple design equations and all required calculations - Offers many graphs that present actual experimental data, figures, and tables, along with explanations




Conceptual Development of Industrial Biotechnology for Commercial Production of Vaccines and Biopharmaceuticals


Book Description

Conceptual Development of Industrial Biotechnology for Commercial Production of Biopharmaceuticals and Vaccines provides insights on how to bring sustainability into biologic drug production. The cumulative facts and figures within in the book are helpful to promoters in monitoring value chain transfer process of super quality biologics for better return in profits. In addition, this is a useful reference for students, researchers and scientists in biotechnology, pharmaceutical science, medical sciences, and the R&D division of biotechnology-based industries. Conceptual development of biotechnology has taken new avenues with the integration of medical sciences, physical science, and engineering, hence this is a timely source. The current global market for vaccines, especially COVID-19, is tremendous. Bivalent oral polio vaccine, diphtheria, tetanus-containing, and measles-containing vaccines have a high demand internationally and recombinant DNA technology and protein engineering are helpful in the production of quality bio-products. - Informs how biotechnology and pharmaceutical industries act as central pillars for the stable production of value-added biological drugs and vaccines from genetically engineered suitable vectors like microbe or cell lines from animals, mammals or plants - Highlights various traditional and modern techniques used for improvising the quality of suitable vectors to produce biologic drugs and vaccines under GMP manufacturing facilities - Provides updated information on the latest microchip-based bioreactors, disposable bag bioreactors, and animal systems as bioreactors to produce biologic drugs like Smart Biomolecules (next generation therapeutics), Bio-similar drugs, Bio-betters, and antibody-drug conjugates - Explains how the closed bioreactors with proper mechanical amendments are used for vaccine production







The Challenge of CMC Regulatory Compliance for Biopharmaceuticals


Book Description

Biopharmaceuticals (i.e., biological medicines sourced from genetically-engineered living systems) for treatment of human diseases have become a significant percentage of the pharmaceutical industry. And not just the recombinant DNA-derived proteins and monoclonal antibodies (both from the innovators and biosimilars); but now, an increasing awareness of the importance of gene therapy and genetically engineered cellular medicinal products. These biopharmaceuticals are being developed by many companies whose Chemistry, Manufacturing & Control (CMC) teams have varying degrees of familiarity or experience with the CMC strategy and regulatory compliance requirements for these challenging products. Companies clearly plan out the strategy for their clinical study plans, but frequently, the development of a strategy for CMC is an afterthought. Coupled with the complexity of the biopharmaceutical manufacturing processes and products, and this can be a recipe for disaster. The third edition of this book provides insights and practical guidance for the CMC teams to develop an acceptable cost-effective, risk-based CMC regulatory compliance strategy for all biopharmaceuticals (recombinant proteins, monoclonal antibodies, genetically engineered viruses and genetically engineered human cells) from early clinical stage development through market approval. The third edition of this book provides added coverage for the biosimilars, antibody drug conjugates (ADCs), bispecific antibodies, genetically engineered viruses, and genetically engineered cells. This third edition of the book also addresses the heightened pressure on CMC regulatory compliance timelines due to the introduction of expedited clinical pathways moving the clinical development closer to a seamless phase process (e.g., FDA Breakthrough Therapy designation, CBER Regenerative Medicine Advanced Therapy (RMAT) designation, EMA Priority Medicines (PRIME) designation). The Challenge of CMC Regulatory Compliance for Biopharmaceuticals is essential, practical information for all pharmaceutical development scientists, Manufacturing and Quality Unit staff, Regulatory Affairs personnel, and senior management involved in the manufacture of biopharmaceuticals.




Advanced Biologic Drugs and Manufacturing Process


Book Description

Advanced Biologic Drugs and Manufacturing Process explains biologic drugs, their pharmaceutical charters, and their significance in curing life-threatening chronic diseases. It also provides the latest information on the use of biological drugs for the treatment of numerous diseases and conditions and their most advanced therapies available, including how biologics have impacted cancer therapy, delayed or reversed the course of immune-related conditions, and changed the lives of those with rare chronic diseases. In addition, the book explains how immunotherapy is used for the treatment of diseases by activating or suppressing the immune system.Scientists working on the front lines in the biotechnology industry are provided with an overview on stable production processes and how to monitor the value chain transfer process of biologic drug for better return, in terms of profit. The book also helps researchers and academics on how to develop and update protocols related to testing, quality control, and quality assurance to obtain highly purified biopharmaceuticals or vaccines. - Gives insights into the conceptual strategic drive for manufacturing innovative, biologically derived therapeutic compounds to launch for commercial purposes - Focuses on how to execute biopharmaceutical portfolio trends to bring sustainable manufacturing processes per the guidelines of international regulatory acts - Highlights the emerging trends in medical sciences on tissue engineering, regenerative medicine, personalized medicines, and various innovative technique on immunotherapy to fight against life-threatening diseases




Registries for Evaluating Patient Outcomes


Book Description

This User’s Guide is intended to support the design, implementation, analysis, interpretation, and quality evaluation of registries created to increase understanding of patient outcomes. For the purposes of this guide, a patient registry is an organized system that uses observational study methods to collect uniform data (clinical and other) to evaluate specified outcomes for a population defined by a particular disease, condition, or exposure, and that serves one or more predetermined scientific, clinical, or policy purposes. A registry database is a file (or files) derived from the registry. Although registries can serve many purposes, this guide focuses on registries created for one or more of the following purposes: to describe the natural history of disease, to determine clinical effectiveness or cost-effectiveness of health care products and services, to measure or monitor safety and harm, and/or to measure quality of care. Registries are classified according to how their populations are defined. For example, product registries include patients who have been exposed to biopharmaceutical products or medical devices. Health services registries consist of patients who have had a common procedure, clinical encounter, or hospitalization. Disease or condition registries are defined by patients having the same diagnosis, such as cystic fibrosis or heart failure. The User’s Guide was created by researchers affiliated with AHRQ’s Effective Health Care Program, particularly those who participated in AHRQ’s DEcIDE (Developing Evidence to Inform Decisions About Effectiveness) program. Chapters were subject to multiple internal and external independent reviews.




Lyophilized Biologics and Vaccines


Book Description

This book provides a detailed account of the most recent developments, challenges and solutions to seamlessly advance and launch a lyophilized biologics or vaccine product, based on diverse modalities, ranging from antibodies (e.g., monoclonal, fused), complex biologics (e.g., antibody drug conjugate, PEGylated proteins), and vaccines (e.g., recombinant-protein based). The authors adeptly guide the reader through all crucial aspects, from biophysical and chemical stability considerations of proteins, analytical methods, advances in controlled ice nucleation and quality-by-design approaches, alternate drying technology, to latest regulatory, packaging and technology transfer considerations to develop a stable, safe and effective therapeutic protein, vaccine and biotechnology products. Lyophilized Biologics and Vaccines: Modality-Based Approaches is composed of four sections with a total of 17 chapters. It serves as a reference to all critical assessments and steps from early pre-formulation stages to product launch: Provides recent understanding of heterogeneity of protein environment and selection of appropriate buffer for stabilization of lyophilized formulations Details the latest developments in instrumental analysis and controlled ice nucleation technology Explains in-depth lyophilized (or dehydrated) formulation strategies considering diverse modalities of biologics and vaccines, including plasmid DNA and lipid-based therapeutics Details an exhaustive update on quality-by-design and process analytical technology approaches, illustrated superbly by case studies and FDA perspective Provides the latest detailed account of alternate drying technologies including spray drying, bulk freeze-drying and crystallization, supported exceptionally by case studies Provides a step-by-step guide through critical considerations during process scale-up, technology transfer, packaging and drug delivery device selection, for a successful lyophilization process validation, regulatory submission and product launch Chapters are written by one or more world-renowned leading authorities from academia, industry or regulatory agencies, whose expertise cover lyophilization of the diverse modalities of biopharmaceuticals. Their contributions are based on the exhaustive review of literature coupled with excellent hands-on experiences in laboratory or GMP setup, making this an exceptional guide to all stages of lyophilized or dehydrated product development.